Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriel Steg

Showing results (531-540 of 962) with videos related to

Pageof 97
Sort By:
American Heart Journal|October 3, 2002
Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention: an expert consensusDean J Kereiakes, Gilles Montalescot, Elliott M Antman, et al.
Circulation. Cardiovascular Interventions|August 13, 2017
Cangrelor in Older Patients Undergoing Percutaneous Coronary Intervention: Findings From CHAMPION PHOENIXMatthew A Cavender, Deepak L Bhatt, Gregg W Stone, et al.
Stroke|July 18, 2013
Overlap of diseases underlying ischemic stroke: the ASCOD phenotypingGaia Sirimarco, Philippa C Lavallée, Julien Labreuche, et al.
Circulation. Cardiovascular Genetics|March 10, 2015
NLRC4 Inflammasome Is an Important Regulator of Interleukin-18 Levels in Patients With Acute Coronary Syndromes: Genome-Wide Association Study in the PLATelet inhibition and patient Outcomes Trial (PLATO)Åsa Johansson, Niclas Eriksson, Richard C Becker, et al.
Journal of the American College of Cardiology|February 21, 2019
Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary StentingFrancesco Costa, David Van Klaveren, Fausto Feres, et al.
Nature Reviews. Cardiology|January 23, 2026
Residual cardiovascular risk in coronary artery disease: from pathophysiology to established and novel therapiesMattia Galli, Antonio Abbate, Marc P Bonaca, et al.
NPJ Digital Medicine|March 20, 2025
Credibility assessment of a mechanistic model of atherosclerosis to predict cardiovascular outcomes under lipid-lowering therapyYishu Wang, Eulalie Courcelles, Emmanuel Peyronnet, et al.
American Heart Journal|July 31, 2013
Comparative prognostic value of T-wave inversion and ST-segment depression on the admission electrocardiogram in non-ST-segment elevation acute coronary syndromesNigel S Tan, Shaun G Goodman, Raymond T Yan, et al.
Journal of the American College of Cardiology|July 25, 2009
Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trialSanjit S Jolly, David P Faxon, Keith A A Fox, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|February 22, 2022
Economic evaluation of fractional flow reserve-guided versus angiography-guided multivessel revascularisation in ST-segment elevation myocardial infarction patients in the FLOWER-MI randomised trialAlicia Le Bras, Etienne Puymirat, Hasina Rabetrano, et al.
Pageof 97

Showing results (531-540 of 962) with videos related to

Sort By:
Pageof 97
American Heart Journal|October 3, 2002
Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention: an expert consensusDean J Kereiakes, Gilles Montalescot, Elliott M Antman, et al.
Circulation. Cardiovascular Interventions|August 13, 2017
Cangrelor in Older Patients Undergoing Percutaneous Coronary Intervention: Findings From CHAMPION PHOENIXMatthew A Cavender, Deepak L Bhatt, Gregg W Stone, et al.
Stroke|July 18, 2013
Overlap of diseases underlying ischemic stroke: the ASCOD phenotypingGaia Sirimarco, Philippa C Lavallée, Julien Labreuche, et al.
Circulation. Cardiovascular Genetics|March 10, 2015
NLRC4 Inflammasome Is an Important Regulator of Interleukin-18 Levels in Patients With Acute Coronary Syndromes: Genome-Wide Association Study in the PLATelet inhibition and patient Outcomes Trial (PLATO)Åsa Johansson, Niclas Eriksson, Richard C Becker, et al.
Journal of the American College of Cardiology|February 21, 2019
Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary StentingFrancesco Costa, David Van Klaveren, Fausto Feres, et al.
Nature Reviews. Cardiology|January 23, 2026
Residual cardiovascular risk in coronary artery disease: from pathophysiology to established and novel therapiesMattia Galli, Antonio Abbate, Marc P Bonaca, et al.
NPJ Digital Medicine|March 20, 2025
Credibility assessment of a mechanistic model of atherosclerosis to predict cardiovascular outcomes under lipid-lowering therapyYishu Wang, Eulalie Courcelles, Emmanuel Peyronnet, et al.
American Heart Journal|July 31, 2013
Comparative prognostic value of T-wave inversion and ST-segment depression on the admission electrocardiogram in non-ST-segment elevation acute coronary syndromesNigel S Tan, Shaun G Goodman, Raymond T Yan, et al.
Journal of the American College of Cardiology|July 25, 2009
Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trialSanjit S Jolly, David P Faxon, Keith A A Fox, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|February 22, 2022
Economic evaluation of fractional flow reserve-guided versus angiography-guided multivessel revascularisation in ST-segment elevation myocardial infarction patients in the FLOWER-MI randomised trialAlicia Le Bras, Etienne Puymirat, Hasina Rabetrano, et al.
Pageof 97